ArticleFrontiers in pharmacology2025
Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of Tislelizumab combined with Axitinib in the treatment of intermediate-high risk metastatic clear-cell renal cell carcinoma (ccRCC). Methods: From September 2021 to June 2023, a total of 20 untreated patients with intermediate-high risk metastatic advanced ccRCC from Shandong Provincial Hospital were included in the study. Clinical characteristics and efficacy were analyzed, and adverse events (AEs) were summarized. All patients received Tislelizumab (200 mg every 3 weeks) and Axitinib (5 mg twice daily bid) until disease progression or intolerable toxicity occurred. The primary endpoint was objective response rate (ORR), and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and incidence of adverse reactions (AEs). Results: The median follow-up time was 19.0 months (range, 9.2-24.4 months), and the median treatment cycle was 16 (range, 2-16). Partial response was observed in 14 patients (70%), stable disease in 2 patients (10%), and disease progression in 4 patient (20%). The overall ORR was 70.0%, and the DCR was 80.0%. The 1-year OS rate was 100%. The incidence of any grade AEs was 85% (17/20), and the incidence of grade 3-4 AEs was 15% (3/20). Common AEs included gastrointestinal reactions (60%, 12/20), rash (40%, 8/20), and hypertension (30%, 6/20). Conclusion: Tislelizumab combined with Axitinib as first-line treatment for intermediate-high risk metastatic ccRCC showed significant efficacy and manageable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.